Advertisement
UK markets closed
  • FTSE 100

    7,952.62
    +20.64 (+0.26%)
     
  • FTSE 250

    19,884.73
    +74.07 (+0.37%)
     
  • AIM

    743.26
    +1.15 (+0.15%)
     
  • GBP/EUR

    1.1697
    +0.0003 (+0.03%)
     
  • GBP/USD

    1.2620
    -0.0002 (-0.02%)
     
  • Bitcoin GBP

    55,455.18
    -359.44 (-0.64%)
     
  • CMC Crypto 200

    885.54
    0.00 (0.00%)
     
  • S&P 500

    5,254.35
    +5.86 (+0.11%)
     
  • DOW

    39,807.37
    +47.29 (+0.12%)
     
  • CRUDE OIL

    83.11
    -0.06 (-0.07%)
     
  • GOLD FUTURES

    2,254.80
    +16.40 (+0.73%)
     
  • NIKKEI 225

    40,369.44
    +201.37 (+0.50%)
     
  • HANG SENG

    16,541.42
    +148.58 (+0.91%)
     
  • DAX

    18,492.49
    +15.40 (+0.08%)
     
  • CAC 40

    8,205.81
    +1.00 (+0.01%)
     

PacBio (PACB) New Revio Workflows to Boost Agricultural Output

Pacific Biosciences of California PACB or PacBio collaborated with global agriculture firm, Corteva Agriscience CTVA, to develop innovative workflows that enable high-throughput sequencing of plant and microbial genomes. The workflows streamline DNA extraction and library preparation, allowing Corteva to sequence thousands of samples annually for seed and crop protection research and production. This partnership, which started at the Advances in Genome Biology and Technology Agricultural meeting last year, provides novel end-to-end workflows that are cost-effective and designed to support ultra-high throughput long-read sequencing.

The initial phase of the collaboration involved the development of scaled DNA extraction, shearing and library preparation workflows to characterize Corteva's extensive collection of crop and microbial samples. These workflows were designed to facilitate transformative crop genetic and diversity studies. The engineering involved the use of ultra-high throughput long-read sequencing on PacBio's revolutionary Revio system and Nanobind products.

Significance of New Workflows

PacBio’s collaboration with Corteva Agriscience will support its efforts to offer healthier and more sustainable production of plants to farmers. With the increasing world population, Corteva believes that new methods in the field of crop science are required to sustainably meet the increasing need for food production. The workflows, along with the new long-read sequencing Revio system, will drive the implementation of seed product development tools like CRISPR-Cas gene editing and cutting-edge crop protection solutions.

ADVERTISEMENT

With the successful results of this collaboration, both companies plan to continue expanding sequencing capabilities and sample preparation workflows into new application areas, fostering a long-term partnership dedicated to revolutionizing agriculture.

Industry Prospects

Per a report by Data Bridge, the global genome sequencing market is projected to reach $55.7 billion in 2030 from $16.7 billion in 2022, at a CAGR of 16.2%. Factors like increasing cancer occurrence and the growing applications of next-generation sequencing in cancer research are expected to drive the market.

Given the market potential, the latest launch is expected to significantly strengthen PacBio’s global business.

Pacific Biosciences of California, Inc. Price

 

Pacific Biosciences of California, Inc. Price
Pacific Biosciences of California, Inc. Price

Pacific Biosciences of California, Inc. price | Pacific Biosciences of California, Inc. Quote

 

Recent Developments

Earlier this month, PacBio introduced a new informatics tool, Paraphase, for variant calling, copy number analysis and phasing. It does so by identifying the full sequence of each of the haplotypes for all genes and pseudogenes of the same gene family. Paraphase has been used on various medically relevant genes, including those related to spinal muscular atrophy, congenital adrenal hyperplasia, Ehlers-Danlos syndrome, and hereditary hearing loss and deafness. With the help of this tool, researchers can better understand the underlying genetics of these complex genomic regions. They can also identify the silent carriers of disease-causing mutations.

In March, PacBio started commercial shipment of Revio long-read sequencing system. It is designed to deliver higher throughput on a lower cost, offering exceptional accuracy and direct methylation detection.

The company expects to ship at least 25 Revio systems and plans to scale up going forward. It had received orders of 76 systems during the fourth quarter of 2022. Last month, the company announced robust increase in its Consumables revenues during the same quarter. However, service and other revenues, as well as product sales declined year over year.

Zacks Rank & Stocks to Consider

PacBiocurrently carries a Zacks Rank #3 (Hold).

Some better-ranked stocks from the broader medical space are Becton, Dickinson and Company BDX and Henry Schein HSIC.

Becton, Dickinson and Company, carrying a Zacks Rank #2 (Buy) at present, has an estimated long-term growth of 7.8%. Its earnings surpassed estimates in each of the trailing four quarters, the average surprise being 6.47%.

You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.

BDX’s shares have declined 9.9% against the industry’s 0.7% growth in the past six months.

Henry Schein, carrying a Zacks Rank #2 at present, has an estimated long-term growth of 8.1%. Its earnings surpassed estimates in three of the trailing four quarters and met the same once, the average surprise being 2.97%.

HSIC’s shares have gained 7.8% compared with the industry’s 0.8% growth in the past six months.

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report

Becton, Dickinson and Company (BDX) : Free Stock Analysis Report

Henry Schein, Inc. (HSIC) : Free Stock Analysis Report

Pacific Biosciences of California, Inc. (PACB) : Free Stock Analysis Report

Corteva, Inc. (CTVA) : Free Stock Analysis Report

To read this article on Zacks.com click here.

Zacks Investment Research